Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2024
Event: Entry into a Material Definitive Agreement involving the issuance of a convertible promissory note.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial performance. Key metrics related to the transaction include:
- Principal Amount: $33,750
- Purchase Price: $30,375
- Interest Rate: 10% per annum (increases to 16% upon default)
- Maturity Date: June 20, 2025
- Use of Proceeds: General working capital
Note: The filing does not provide revenue, profit, cash flow, margins, or total debt figures for the company.
Material Changes and Transaction Details
The Company entered into a Securities Purchase Agreement with an investor to issue a convertible promissory note. Key terms include:
- Conversion Terms: The note is convertible into common stock at the investor's option at any time after issuance. The conversion price is 65% of the lowest closing trade price during the 10 trading days prior to conversion (a 35% discount).
- Ownership Limitation: Conversions are subject to a 4.99% beneficial ownership limitation.
- Share Reserve: The Company must maintain a reserve of at least 500% of the number of potential conversion shares.
- Prepayment Rights: The Company may prepay the note with a premium ranging from 110% to 125% of the face amount plus accrued interest, depending on the timing within the first 180 days. No prepayment right exists after 180 days.
Outlook, Risks, and Contingencies
Events of Default: The note includes specific events of default that would make the obligation immediately due and payable, including:
- Failure to pay principal or interest when due.
- Failure to timely issue conversion shares.
- Failure to maintain listing on an OTC market or equivalent exchange.
- Failure to comply with SEC reporting requirements.
- Insolvency, bankruptcy, or liquidation.
Regulatory Status: The securities were issued pursuant to the private placement exemption under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the Company's current cash position to assess the ability to service the 10% interest and potential prepayment premiums.
- Review the Company's recent stock trading volume and price to evaluate the potential dilution impact of the 35% discount conversion feature.
- Confirm the Company's compliance status with SEC reporting requirements to avoid triggering an event of default.
- Check the Company's current listing status on OTC markets to ensure compliance with the note's covenants.
- Examine the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 4.1) for additional covenants not summarized here.